新英格兰医学期刊:阿斯利康去世,奥拉帕尼如何吃的癌症药物奥拉帕尼复生,

  • A+
所属分类:医疗资讯

新英格兰医学期刊:阿斯利康去世,奥拉帕尼如何吃的癌症药物奥拉帕尼复生, 。
奥拉帕尼(利普卓)摘 要:孟加拉国奥拉帕尼。新英格兰医学期刊:阿斯利康去世,奥拉帕尼如何吃的癌症药物奥拉帕尼复生,曾被称为是转换科学研究的辉煌案例,却在一次让人难过的临床试验后遭遇抛下的一种肿瘤药品,目前也许可以涅盘重生。《壹篇》按《新英格兰医科学杂志》2022年6月4日线上先给http://www.nejm.org/doi/full/10.1056/NEJMoa1706450

在BRCA基因变异病患者选用奥拉帕尼医治迁移扩散性乳腺癌

环境奥拉帕尼(Olaparib)是一种内服的聚腺苷二磷酸酯核糖核苷酸汇聚酶抑制剂,在BRCA基因变异的迁移扩散性乳腺癌病患者中有显著的防癌活力。方式大家完成了一项随机化、对外开放标识的3期临床试验,在BRCA基因变异、人表层细胞生长因子蛋白激酶2(HER2)呈阴性的迁移扩散性乳腺癌病患者中,且这种病患者以往对于迁移扩散性乳腺癌所开展的有机化学治疗法方式不超过二种,对奥拉帕尼单药治疗与规范医治开展了较为。将病患者按2:1占比随机分组,内服奥拉帕尼片(300mg,每日2次),或是由医师挑选开展单药有机化学治疗法(卡培他滨、艾瑞布林或长春瑞滨,二十一天一周期时间)的规范医治。关键终端为无进度存活時间,无进度存活時间由盲法、单独审批核心开展点评,在意愿医治基本上开展数据分析。結果在开展随机化排序的302名病患者中,205名分派入奥拉帕尼组、97名排序至规范医治组。奥拉帕尼组负相关无进度存活時间显然比规范医治小组长(7.0个月较为4.2个月,恶性肿瘤进度或过世风险比,0.58;95%可信区间,0.43-0.80;P<0.001)。奥拉帕尼组减轻率是59.9%,规范医治组28.8%。奥拉帕尼组≥3级欠佳(过虑词)发病率为36.6%,规范医治组50.5%,因为慢性毒药不良反应而终断治愈率各自为4.9%和7.7%。结果在BRCA基因变异、HER2呈阴性迁移扩散性乳腺癌病患者中,奥拉帕尼单药治疗比规范诊治的获利更显著,奥拉帕尼单药治疗比规范医治负相关无进度存活時间提升2.8个月、恶性肿瘤进度或过世的风险低42%。南南和晨晨

Olaparib for Metastatic Breast Cancer in Patients with a GermlineBRCAMutation

Mark Robson, M.D., Seock-Ah Im, M.D., Ph.D., Elżbieta Senkus, M.D., Ph.D., Binghe Xu, M.D., Ph.D., Susan M. Domchek, M.D., Norikazu Masuda, M.D., Ph.D., Suzette Delaloge, M.D., Wei Li, M.D., Nadine Tung, M.D., Anne Armstrong, M.D., Ph.D., Wenting Wu, Ph.D., Carsten Goessl, M.D., Sarah Runswick, Ph.D., and Pierfranco Conte, M.D.June 4, 2017DOI: 10.1056/NEJMoa1706450BackgroundOlaparib is an oral poly(新英格兰医学期刊:阿斯利康去世,奥拉帕尼如何吃的癌症药物奥拉帕尼复生,adenosine diphosphate–ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.MethodsWe conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (HER2)–negative metastatic breast cancer who had received no more than two previous chemotherapy regimens for metastatic disease. Patients were randomly assigned, in a 2:1 ratio, to receive olaparib tablets (300 mg twice daily) or standard therapy with single-agent chemotherapy of the physician’s choice (capecitabine, eribulin, or vinorelbine in 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review and was analyzed on an intention-to-treat basis.ResultsOf the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio for disease progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001). The response rate was 59.9% in the olaparib group and 28.8% in the standard-therapy group. The rate of grade 3 or higher adverse events 新英格兰医学期刊:阿斯利康去世,奥拉帕尼如何吃的癌症药物奥拉帕尼复生,was 36.6% in the olaparib group and 50.5% in the standard-therapy group, and the rate of treatment discontinuation due to toxic effects was 4.9% and 7.7%, respectively.ConclusionsAmong patients with HER2-negative metastatic breast cancer and a germline BRCA mutation, olaparib monotherapy provided a significant benefit over standard therapy; median progression-free survival was 2.8 months longer and the risk of disease progression or death was 42% lower with olaparib monotherapy than with standard therapy. (Funded by AstraZeneca; OlympiAD ClinicalTrials.gov number, NCT02000622.)《壹篇》系关键朝向医护人员的服务性【微信号码:yaodaoyaofang】,不因盈利为目地,不开展一切有偿服务资询和服务项目,不销售一切商品,与ASCO、CSCO等全部技术专业学好和组织并没有任何的关联和联络,都不意味着一切官方网学好发音。文章照片均来源于互联网,不做商业行为,若有著作权异议请与《壹篇》联络。不断关注点赞——【手机微信:india2080】、称赞和分享——【手机微信:india2080】是一种心态和适用。
孟加拉国珠穆朗玛峰Everest,耀品国际性制药业产奥拉帕尼 利普卓。印度的全世界海淘药店:奥拉帕尼要多少钱。

  • 微信咨询
  • 这是我的微信扫一扫
  • weinxin
  • WhatsApp 沟通
  • 手机扫一扫二维码
  • weinxin

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: